North China Pharmaceutical Company.Ltd

SHSE:600812 Rapport sur les actions

Capitalisation boursière : CN¥8.6b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

North China Pharmaceutical Company.Ltd Bilan de santé

Santé financière contrôle des critères 2/6

North China Pharmaceutical Company.Ltd has a total shareholder equity of CN¥6.6B and total debt of CN¥11.3B, which brings its debt-to-equity ratio to 172.6%. Its total assets and total liabilities are CN¥21.8B and CN¥15.2B respectively. North China Pharmaceutical Company.Ltd's EBIT is CN¥599.0M making its interest coverage ratio 3.1. It has cash and short-term investments of CN¥1.8B.

Informations clés

172.6%

Ratio d'endettement

CN¥11.31b

Dette

Ratio de couverture des intérêts3.1x
Argent liquideCN¥1.77b
Fonds propresCN¥6.55b
Total du passifCN¥15.20b
Total des actifsCN¥21.75b

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

The Market Doesn't Like What It Sees From North China Pharmaceutical Company.Ltd's (SHSE:600812) Revenues Yet

Apr 26
The Market Doesn't Like What It Sees From North China Pharmaceutical Company.Ltd's (SHSE:600812) Revenues Yet

Analyse de la situation financière

Passif à court terme: 600812's short term assets (CN¥8.8B) do not cover its short term liabilities (CN¥11.4B).

Passif à long terme: 600812's short term assets (CN¥8.8B) exceed its long term liabilities (CN¥3.8B).


Historique et analyse du ratio d'endettement

Niveau d'endettement: 600812's net debt to equity ratio (145.6%) is considered high.

Réduire la dette: 600812's debt to equity ratio has increased from 152.7% to 172.6% over the past 5 years.

Couverture de la dette: 600812's debt is not well covered by operating cash flow (14.5%).

Couverture des intérêts: Les paiements d'intérêts de 600812 sur sa dette sont bien couverts par l'EBIT ( 3.1 x couverture).


Bilan


Découvrir des entreprises saines